Pomdoctor Limited, a leading online healthcare platform for chronic disease management in China, announced substantial progress in its collaborations with major domestic pharmaceutical companies to accelerate the expansion of its internet hospital operations. These partnerships are expected to play a key role in Pomdoctor’s long-term strategy, supporting nationwide growth and improving overall profitability.
Health Technology Insights: OrthAlign Expands Lantern Hip Platform for Posterior THA
China’s aging population and shifting demographics have driven rapid growth in the online healthcare and pharmaceutical markets. Data from Yaozh.com shows that online drug sales in China rose from approximately RMB 19 billion in 2020 to RMB 60.8 billion in 2023, reaching RMB 71.8 billion about US$10.3 billion in 2024, reflecting a compound annual growth rate of 39.4 percent. Pomdoctor is leveraging these trends by deepening collaborations with pharmaceutical companies to expand its coverage, increase market presence, and deliver innovative products to its platforms.
Over the past few years, Pomdoctor, through its subsidiaries, has signed sales and purchase agreements with leading companies including Jiangsu Haosoh Pharmaceutical Group, Xiamen Amoytop Biotech, Shenyang Sinqi Pharmaceutical, and Eddingpharm Suzhou. These collaborations allow Pomdoctor to offer innovative and patented medicines to patients and healthcare providers while providing pharmaceutical partners with efficient digital sales channels. Under the agreements, Pomdoctor receives purchase discounts, rebates, and performance-based incentives tied to sales targets.
Health Technology Insights: Solventum Wins Diamond HIRC Badge for Top Supply Chain Strength
Zhenyang Shi, Chairman and CEO of Pomdoctor, said the Chinese online pharmaceutical market provides tremendous growth opportunities for both drug manufacturers and digital healthcare platforms. He emphasized that Pomdoctor’s partnership model creates a win-win situation by integrating each partner’s strengths cost-effectively. He added that manufacturers gain greater control over distribution, reduce dependency on traditional large distributors, improve cash flow, and reach target audiences more directly. For Pomdoctor, direct sourcing from trusted manufacturers ensures competitive pricing, consistent product supply, and enhanced service quality. Most importantly, patients and pharmacies benefit from wider access to medications, better pricing, and greater reliability.
Mr. Shi explained that this approach represents a natural evolution of China’s healthcare supply chain by flattening the distribution process, reducing unnecessary intermediaries, and increasing transparency. The model focuses on digital collaboration, data sharing, and long-term value creation rather than simply transactional relationships, positioning Pomdoctor as a leader in the modernization of pharmaceutical distribution in China.
Health Technology Insights: Ferronova Raises $6 Million to Boost Image-Guided Cancer Surgery
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
